Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA and Arsenic Trioxide for APL
NCT00528450Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2007
- Primary completion
- Jan 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in acute promyelocytic leukemia (APL), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2007; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00528450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528450.